LT2632467T - Cdk inhibitoriai - Google Patents

Cdk inhibitoriai

Info

Publication number
LT2632467T
LT2632467T LTEP11838545.9T LT11838545T LT2632467T LT 2632467 T LT2632467 T LT 2632467T LT 11838545 T LT11838545 T LT 11838545T LT 2632467 T LT2632467 T LT 2632467T
Authority
LT
Lithuania
Prior art keywords
cdk inhibitors
cdk
inhibitors
Prior art date
Application number
LTEP11838545.9T
Other languages
English (en)
Inventor
Francis X. Tavares
Jay C. Strum
Original Assignee
G1 Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2632467(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics, Inc. filed Critical G1 Therapeutics, Inc.
Publication of LT2632467T publication Critical patent/LT2632467T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP11838545.9T 2010-10-25 2011-10-25 Cdk inhibitoriai LT2632467T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40649810P 2010-10-25 2010-10-25
PCT/US2011/057749 WO2012061156A1 (en) 2010-10-25 2011-10-25 Cdk inhibitors

Publications (1)

Publication Number Publication Date
LT2632467T true LT2632467T (lt) 2016-09-12

Family

ID=46024778

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11838545.9T LT2632467T (lt) 2010-10-25 2011-10-25 Cdk inhibitoriai

Country Status (25)

Country Link
US (2) US8598197B2 (lt)
EP (6) EP3118203B1 (lt)
JP (4) JP5923509B2 (lt)
KR (4) KR20200137048A (lt)
CN (5) CN104045654A (lt)
AU (5) AU2011323739B2 (lt)
BR (1) BR112013010018B1 (lt)
CA (2) CA2815084C (lt)
CY (1) CY1118004T1 (lt)
DK (1) DK2632467T3 (lt)
ES (1) ES2592515T3 (lt)
HK (2) HK1197067A1 (lt)
HR (1) HRP20161092T1 (lt)
HU (1) HUE030714T2 (lt)
IL (5) IL225940A0 (lt)
LT (1) LT2632467T (lt)
MX (4) MX379532B (lt)
PL (1) PL2632467T3 (lt)
PT (1) PT2632467T (lt)
RS (1) RS55135B1 (lt)
RU (1) RU2621674C2 (lt)
SG (2) SG10201508715YA (lt)
SI (1) SI2632467T1 (lt)
SM (1) SMT201600311B (lt)
WO (1) WO2012061156A1 (lt)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20217221B (en) 2005-05-10 2021-02-10 Incyte Holdings Corp Us Modulators of indoleamine 2,3-dioxygenase and methods of using the same
PT2824100T (pt) 2008-07-08 2018-05-10 Incyte Holdings Corp 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
HRP20170430T1 (hr) 2012-06-13 2017-06-16 Incyte Holdings Corporation Supstituirani triciklični spojevi kao inhibitori fgfr
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
WO2014144596A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
CN107417691B (zh) * 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
PL2986610T4 (pl) 2013-04-19 2019-06-28 Incyte Holdings Corporation Bicykliczne heterocykle jako inhibitory FGFR
WO2015161283A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MY197720A (en) 2015-02-20 2023-07-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AU2017290362B2 (en) 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
JP2019520379A (ja) * 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
ES2966469T3 (es) 2016-08-23 2024-04-22 Eisai R&D Man Co Ltd Terapias combinadas para el tratamiento del carcinoma hepatocelular
US10849903B2 (en) 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
JP6905069B2 (ja) * 2016-11-11 2021-07-21 上海海雁醫藥科技有限公司 ピリジルアミノ置換へテロ三環式化合物並びにその製造方法及び医薬用途
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
CN110325191A (zh) 2017-02-22 2019-10-11 G1治疗公司 以较少的副作用治疗egfr-驱动的癌症
IL269357B2 (en) 2017-03-16 2024-10-01 Eisai R&D Man Co Ltd A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2988261T3 (es) 2017-06-29 2024-11-19 G1 Therapeutics Inc Formas mórficas de GIT38 y métodos de fabricación de las mismas
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
RU2020123665A (ru) 2018-01-08 2022-02-10 Г1 Терапьютикс, Инк. Преимущественные режимы дозирования g1т38
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020041770A1 (en) 2018-08-24 2020-02-27 G1 Therapeutics, Inc. Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
RS66424B1 (sr) 2018-09-10 2025-02-28 Mirati Therapeutics Inc Kombinovane terapije
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN111377935B (zh) * 2018-12-29 2021-06-29 武汉光谷通用名药物研究院有限公司 选择性cdk4/6抑制剂及其应用
CN111377924A (zh) * 2018-12-29 2020-07-07 武汉光谷通用名药物研究院有限公司 新型cdk4抑制剂及其用途
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
CA3130210A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202114684A (zh) 2019-06-18 2021-04-16 美商G1治療公司 增強癌症病患之抗腫瘤免疫之方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550246A1 (en) 2019-08-01 2023-06-26 Incyte Corp A dosing regimen for an ido inhibitor
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115298177B (zh) 2019-10-11 2025-01-17 因赛特公司 作为cdk2抑制剂的双环胺
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
US20210355121A1 (en) 2020-04-16 2021-11-18 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
EP4153597B1 (en) 2020-05-19 2025-09-10 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
MX2022015567A (es) 2020-06-11 2023-01-19 Lunella Biotech Inc Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6.
EP4164653A4 (en) * 2020-06-15 2024-06-19 G1 Therapeutics, Inc. MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022076779A1 (en) * 2020-10-08 2022-04-14 Teva Pharmaceuticals International Gmbh Solid state forms of trilaciclib and of trilaciclib salts
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
KR20240032915A (ko) 2021-07-07 2024-03-12 인사이트 코포레이션 Kras의 저해제로서의 삼환식 화합물
EP4370515A1 (en) 2021-07-14 2024-05-22 Incyte Corporation Tricyclic compounds as inhibitors of kras
MX2024001266A (es) 2021-07-26 2024-04-16 Celcuity Inc 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
EP4396187A1 (en) 2021-08-31 2024-07-10 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
GEAP202416515A (en) 2021-10-14 2024-07-25 Incyte Corp Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
IL313735A (en) 2021-12-22 2024-08-01 Incyte Corp Salts and solid forms of Pajfer inhibitor and processes for their preparation
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｃｄｋ２抑制劑及其用途
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
WO2023164255A1 (en) 2022-02-28 2023-08-31 Teva Pharmaceuticals International Gmbh Crystalline forms of trilaciclib and trilaciclib salts
IL315457A (en) 2022-03-07 2024-11-01 Incyte Corp Solid forms, salts and preparation processes of the Sidikii2 inhibitor
US20250353842A1 (en) 2022-06-22 2025-11-20 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN115536663A (zh) * 2022-10-11 2022-12-30 杭州科巢生物科技有限公司 一种曲拉西利中间体及其制备与应用
WO2024116069A1 (en) * 2022-11-28 2024-06-06 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof
GEAP202616866A (en) 2023-04-18 2026-02-10 Incyte Corp 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
EP4704850A1 (en) 2023-05-04 2026-03-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IT202300010182A1 (it) 2023-05-19 2024-11-19 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2024246713A1 (en) * 2023-05-29 2024-12-05 Fresenius Kabi Oncology Ltd A process for the preparation of cdk inhibiting pyrrolopyrimidine compounds
IT202300010824A1 (it) * 2023-05-29 2024-11-29 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025134057A1 (en) 2023-12-20 2025-06-26 Assia Chemical Industries Ltd. Solid state forms of trilaciclib citrate salt
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026044119A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026060143A1 (en) 2024-09-11 2026-03-19 Incyte Corporation Kras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006094A1 (en) * 1990-10-09 1992-04-16 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
EP1467995B1 (en) * 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
AP1767A (en) 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
US20040127492A1 (en) * 2002-02-19 2004-07-01 Pharmacia Corporation Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EA010904B1 (ru) * 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EP1678177B1 (en) 2003-10-23 2007-11-28 F.Hoffmann-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
GB0327380D0 (en) * 2003-11-25 2003-12-31 Cyclacel Ltd Method
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
SI2125822T1 (sl) * 2006-12-21 2015-01-30 Nerviano Medical Sciences S.R.L. Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze
AU2008268442A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
NZ591176A (en) * 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
JP2012504645A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
AU2009298367A1 (en) 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
EP2831080B1 (en) * 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors

Also Published As

Publication number Publication date
CN103429243A (zh) 2013-12-04
MX367795B (es) 2019-09-06
PL2632467T3 (pl) 2016-12-30
KR102051881B1 (ko) 2019-12-04
CA2961937A1 (en) 2012-05-10
AU2011323739A1 (en) 2013-05-02
IL271977A (en) 2020-02-27
EP3381920A1 (en) 2018-10-03
IL252108B (en) 2020-02-27
DK2632467T3 (en) 2016-08-15
AU2020203035A1 (en) 2020-05-28
SI2632467T1 (sl) 2016-10-28
HK1197067A1 (en) 2015-01-02
IL237582A0 (en) 2015-04-30
RU2621674C2 (ru) 2017-06-07
AU2020203037B2 (en) 2021-09-09
AU2011323739B2 (en) 2016-05-12
EP3981770A1 (en) 2022-04-13
KR20190135556A (ko) 2019-12-06
CN104045654A (zh) 2014-09-17
EP3567042B1 (en) 2021-07-07
SG10201508715YA (en) 2015-11-27
US8598186B2 (en) 2013-12-03
WO2012061156A1 (en) 2012-05-10
US20130237544A1 (en) 2013-09-12
KR20180135086A (ko) 2018-12-19
CN103429243B (zh) 2016-06-08
IL237581B (en) 2018-11-29
EP3381920B1 (en) 2019-03-27
EP2632467B1 (en) 2016-06-22
KR101929593B1 (ko) 2018-12-14
BR112013010018B1 (pt) 2020-11-10
ES2592515T3 (es) 2016-11-30
JP2018193400A (ja) 2018-12-06
EP2632467A1 (en) 2013-09-04
AU2018202991A1 (en) 2018-05-17
MX2019010602A (es) 2019-10-17
JP2016183161A (ja) 2016-10-20
JP2017186357A (ja) 2017-10-12
CA2815084A1 (en) 2012-05-10
BR112013010018A2 (pt) 2016-08-02
JP5923509B2 (ja) 2016-05-24
RU2013123790A (ru) 2014-12-10
EP2955183A1 (en) 2015-12-16
EP2632467A4 (en) 2014-03-26
JP6157680B2 (ja) 2017-07-05
CN103936745B (zh) 2017-04-12
AU2016204879A1 (en) 2016-07-28
AU2018202991B2 (en) 2020-02-13
MX338327B (es) 2016-04-12
JP6389926B2 (ja) 2018-09-12
MX385616B (es) 2025-03-18
PT2632467T (pt) 2016-08-29
CN106008533B (zh) 2018-01-23
HK1254345B (en) 2020-04-09
CA2815084C (en) 2017-05-09
CA2961937C (en) 2018-09-25
CN103936745A (zh) 2014-07-23
SMT201600311B (it) 2016-11-10
SG189525A1 (en) 2013-05-31
KR102186969B1 (ko) 2020-12-04
US8598197B2 (en) 2013-12-03
IL252108A0 (en) 2017-07-31
MX379532B (es) 2025-03-10
JP2013543845A (ja) 2013-12-09
MX2013004681A (es) 2013-10-17
HUE030714T2 (en) 2017-05-29
KR20200137048A (ko) 2020-12-08
HRP20161092T1 (hr) 2016-10-21
CN106008533A (zh) 2016-10-12
IL237581A0 (en) 2015-04-30
RS55135B1 (sr) 2016-12-30
IL225940A0 (en) 2013-06-27
MX2020005498A (es) 2021-08-26
CN106967074A (zh) 2017-07-21
AU2020203035B2 (en) 2021-09-16
EP3567042A1 (en) 2019-11-13
IL271977B (en) 2021-04-29
AU2020203037A1 (en) 2020-05-28
AU2016204879B2 (en) 2018-02-01
EP3118203B1 (en) 2018-10-24
CY1118004T1 (el) 2017-05-17
US20130237533A1 (en) 2013-09-12
EP3118203A1 (en) 2017-01-18
KR20140003427A (ko) 2014-01-09

Similar Documents

Publication Publication Date Title
IL252108A0 (en) cdk inhibitors
GB201004179D0 (en) Enzyme inhibitors
GB2498145B (en) Releasable corrosion inhibitors
GB201004178D0 (en) Enzyme inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
PL2563771T3 (pl) Związki inhibitora metaloenzymu
GB201004311D0 (en) New enzyme inhibitor compounds
GB201009731D0 (en) Kinase inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
GB201018996D0 (en) Novel ROCK inhibitors
ZA201303360B (en) Kat ii inhibitors
GB201009853D0 (en) HSP90 inhibitors
EP2521451A4 (en) INHIBITORS OF THE HEDGEHOG PATH
GB201020798D0 (en) Corrosion inhibitors
EP2632903A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201018480D0 (en) Factors
EP2651905A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
ZA201303412B (en) Kat ii inhibitors
GB201018597D0 (en) Inhibitors
GB201004309D0 (en) New enzyme inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors